Thursday, January 25, 2018 6:35:10 AM
Important to note 2 points
1. “ with FDA permission, is to next proceed with a Phase 1 clinical trial in healthy volunteers using the oral route. “
2. Half life of oral dose - 1 hour
Point 1 means - K is going back to ground zero with oral - phase 1 and not even 1a - healthy volunteers - then P1a with sick patients then P2 for dose optimization and efficacy and then P3.
This means all efforts for last 4-5 years established that K is non-toxic and more like water and cannot be used as a effective drug
All this after oral formulation is completed and available.
Co has not given any update on oral formulation progress.
Good luck with K - wait for another 3 years to go to P2
2. Oral half life 1 hour - it is so short that to reach therapeutic level for any cancer they will have to give high dosage such as 500 mg - 2 tablets every 2 hours and this can bring side effects
In the end patient will eat K tablets as breakfast lunch and dinner no other food.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM